Key Client Fiduciary Advisors LLC Has $277,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Key Client Fiduciary Advisors LLC decreased its position in Amgen Inc. (NASDAQ:AMGNFree Report) by 4.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 961 shares of the medical research company’s stock after selling 47 shares during the period. Key Client Fiduciary Advisors LLC’s holdings in Amgen were worth $277,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Southland Equity Partners LLC boosted its stake in Amgen by 2.3% in the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after purchasing an additional 34 shares during the period. Quantum Financial Advisors LLC boosted its stake in shares of Amgen by 1.3% during the 4th quarter. Quantum Financial Advisors LLC now owns 2,954 shares of the medical research company’s stock valued at $851,000 after buying an additional 38 shares during the period. Gray Wealth Management Inc. boosted its stake in shares of Amgen by 3.3% during the 2nd quarter. Gray Wealth Management Inc. now owns 1,206 shares of the medical research company’s stock valued at $268,000 after buying an additional 39 shares during the period. Hutchinson Capital Management CA boosted its stake in shares of Amgen by 3.0% during the 3rd quarter. Hutchinson Capital Management CA now owns 1,360 shares of the medical research company’s stock valued at $365,000 after buying an additional 39 shares during the period. Finally, Tiemann Investment Advisors LLC boosted its stake in shares of Amgen by 3.1% during the 2nd quarter. Tiemann Investment Advisors LLC now owns 1,334 shares of the medical research company’s stock valued at $296,000 after buying an additional 40 shares during the period. Institutional investors and hedge funds own 74.44% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $268.87 on Friday. The firm’s 50-day moving average is $294.66 and its 200-day moving average is $279.49. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The company has a market cap of $144.09 billion, a price-to-earnings ratio of 21.53, a PEG ratio of 2.59 and a beta of 0.58.

Amgen (NASDAQ:AMGNGet Free Report) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same period in the previous year, the business earned $4.09 EPS. The firm’s revenue was up 19.8% on a year-over-year basis. Equities research analysts anticipate that Amgen Inc. will post 19.48 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.35%. Amgen’s payout ratio is 72.06%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research reports. SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $324.00 to $318.00 in a research note on Wednesday, February 7th. Oppenheimer restated an “outperform” rating and set a $350.00 price target on shares of Amgen in a report on Thursday, February 1st. BMO Capital Markets upgraded shares of Amgen from a “market perform” rating to an “outperform” rating and raised their price target for the company from $286.00 to $326.00 in a report on Tuesday, December 19th. Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and raised their price target for the company from $264.00 to $320.00 in a report on Thursday, December 21st. Finally, The Goldman Sachs Group raised their price target on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $295.30.

Get Our Latest Report on AMGN

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

See Also

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.